Web 3.0 has an impact on traditional sectors in addition to the Internet. Decentralized organizations are attempting to change the closed access or difficult replication of many scientific breakthroughs.
The biotechnology sector has utilized centralized structures for many years. Typically, government funding is used by scientists to study the illness, after which private corporations acquire the rights to their patents. More and more groups are working to develop an alternative to this framework and increase the democratic nature of the intellectual property and data in the natural sciences.
The top five biotechnology-related Web 3.0 initiatives are shown below.
A stable industry standard for funding biotechnological research and early-stage drug development programs was intended when BioDAO was developed. This DAO aims to get clear of traditional investors’ prejudices against “star” laboratories and repeat biotech company entrepreneurs.
CureDAO is an open-source platform created to look at how different foods, medications, and dietary supplements affect people’s health.
A initiative from the UK called GenomesDAO offers itself as a competitor to well-known D2C genome sequencing businesses like 23andMe. By analyzing the client’s genome, these services promise to give him individualized information on his ancestry and health. However, they frequently collect and sell user data.
The same services are provided by GenomesDAO, but the data is stored in the business’ blockchain, where it is encrypted and only accessible with the user’s permission.
The objective of the network of scientists and engineers known as LabDAO is to give its members access to a wide variety of computing and laboratory instruments. The DAO is striving to remove obstacles, such as high cost, trade secrets, and data that cannot be replicated, that impede access to life sciences for everyone, just how open source has contributed to the development of information technology for decades.
Decentralized medicine development is something that VitaDAO advocates for, particularly in the area of longevity. It aims to do away with a typical drawback of the present biopharmaceutical model: the ownership of intellectual property by private corporations, whose research and development is frequently less effective. Both researchers and patients are impacted by all of this.